To combat mischievous coronavirus disease followed by continuous upgrading of
therapeutic strategy against the antibody-resistant variants, the molecular mechanistic …

Numerous viral pneumonia cases have been reported in Wuhan, Hubei in December 2019.
The pathogen has been identified as a novel coronavirus, which was named severe acute …

Despite the continued spread of SARS-CoV-2 and emergence of variants of concern (VOC)
that are capable of escaping preexisting immunity, therapeutic options are underutilized. In …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the
COVID-19 pandemic, has infected over 260 million people over the past 2 years. Remdesivir …

Paragraph SARS-CoV-2 variants of concern (VOC) have triggered distinct infection waves in
the coronavirus disease 2019 (COVID-19) pandemic, culminating in currently all-time high …

The antiviral component of Paxlovid, nirmatrelvir (NIR), forms a covalent bond with Cys145
of SARS-CoV-2 nsp5. To explore NIR resistance we designed mutations to impair binding of …

As remdesivir, the first FDA-approved drug for SARS-CoV-2 infection, can be used only for
hospitalized patients due to intravenous administration, there is an urgent need of effective …

SARS-CoV-2 continues to spread in the population. We recently reported the production of
bovine colostrum-derived antibodies that can neutralize the virus. These have been …

The urgent response to the COVID-19 pandemic required accelerated evaluation of many
approved drugs as potential antiviral agents against the causative pathogen, severe acute …

Background: Recent trials have highlighted the potential of oral antiviral VV116 in the
treatment of patients with mild COVID-19. However, no comprehensive studies have …